HALO vs SCHW · P/E 15, rev $857.7M vs P/E 19, rev $13.55B
Halozyme Therapeutics Inc (HALO) versus Charles Schwab Corp (SCHW) — a side-by-side from cached financials, not a winner call.
Halozyme Therapeutics Inc (HALO) is a biotechnology company listed on US.
Charles Schwab Corp (SCHW) is a capital markets company listed on NYSE. It is led by Richard Andrew Wurster C.F.A., CMT.
Latest reported HALO revenue for 2026-06-30 was $857.7M. Net income was $380.0M. HALO currently screens at market cap $7.10B and trailing P/E 15.3.
Latest reported SCHW revenue for 2026-06-30 was $13.55B. Net income was $5.28B. SCHW currently screens at market cap $164.37B and trailing P/E 18.8.
HALO currently screens at market cap $7.10B and trailing P/E 15.3. SCHW currently screens at market cap $164.37B and trailing P/E 18.8.
Not investment advice. Open the HALO and SCHW stock pages for the full models.
Not investment advice.